The Annual Cardio Renal Connections meeting is a unique two-day continuing education activity bringing together clinicians and scientists to explore the complex relationships between the heart, kidney and metabolic systems. The importance of this nexus is particularly relevant given the aging population of the United States and the growing epidemic of obesity and diabetes. The goal of this CE program is to help foster education, research and discussion about the intersection of these pathophysiological systems.
Who Should Attend
This is a conference for healthcare professionals: academic & community physicians, PhDs, nurses, pharmacists, nurse practitioners, dietitians, social workers, residents, fellows, and students.
Continuing Education Credit:
Continuing Medical Education (CME)
The UT Health San Antonio Joe R. and Teresa Lozano Long School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Long School of Medicine designates this live activity up to a maximum of 19.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education (CNE)
15.33 contact hours will be awarded to registered nurses upon completion of both days of the conference.
7.67 contact hours will be awarded to registered nurses upon completion of one day of the conference.
The University of Texas Health Science Center at San Antonio School of Nursing is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Continuing Pharmacy Education (CPE)
Continuing pharmacy education (CPE) credit may be claimed for all sessions. Proof of attendance will be provided and will contain the information required by the Texas State Board of Pharmacy to claim CPE .
Commission on Dietetic Registration (CDR)
The Long School of Medicine is a Continuing Professional Education (CPE) Accredited
provider with the Commission on Dietetic Registration (CDR). Activity #152796 is approved by the Texas State Affiliate.
Texas Medical Board – Ethics Statement
† 2.0 hours meets the Texas Medical Board criteria for formal continuing medical education involving the study of medical ethics and/or professional responsibility.
• In-depth exploration of the interactions between obesity, diabetes, heart and kidney disease
• Latest pharmacological interventions for diabetes with cardiorenal protections
• Ketogenic vs. Mediterranean diet vs. bariatric surgery approaches for heart and kidney patients
• Updates on peripheral vascular disease and its management in kidney patients
• Latest in understanding of the renal risks associated with contrast dye administration and approaches to mitigate the risks.
• Role of kidney transplantation for Cardiovascular disease
• State of the art in hypertension management including measurement techniques and BP goals
• Nephrology on the cutting edge: learn about APOL1, PLA2R, Tolvaptan, latest phosphate and potassium binders
• Innovation in heart failure management
• Controversies of current era: use of aspirin for prevention and cholesterol/triglyceride management in kidney patients
• Reflection on humanistic side of medicine, patient-physician relationship
Anand Prasad, MD, FACC, FSCAI, RPVI
Dr. Prasad graduated from Louisiana State University School of Medicine in New Orleans in 2000. He completed Internal Medicine and Cardiology training at the University of Texas Southwestern at Dallas. Subsequently, he completed an Interventional Cardiology and an Endovascular Fellowship at the University of California San Diego. He then joined the faculty at UC San Diego and after three years moved back to Texas to join the faculty at UT Health Science Center at San Antonio as an Assistant Clinical Professor. He is currently an Associate Professor of Medicine and holds the Freeman Heart Association Endowment in Cardiovascular Disease. He also is the Director of the Cardiac Catheterization Laboratory at University Health System. His clinical interests are centered on the endovascular treatment of peripheral arterial disease including carotid and lower extremity disease, transcatheter aortic valve replacement, percutaneous ventricular support devices and complex high risk percutaneous coronary interventions. Dr. Prasad has a focus on Vascular Medicine, is also board certified by the American Board of Vascular Medicine, and holds a certification as a Registered Physician in Vascular Interpretation (RPVI). He conducts a monthly Vascular Medicine Clinic and is constructing a vascular imaging and venous ablation program at UT Health.
He has served as the Associate Program Director and Program Director for the Cardiovascular Diseases Fellowship Program at UT Health San Antonio. In addition to an active role in Fellow training, Dr. Prasad is involved with clinical research. He is the PI on both investigator-initiated and industry-sponsored clinical trials. His areas of current interest include novel approaches to therapy for limb salvage and acute kidney injury following endovascular interventions. He is also involved with efforts to understand subclinical vascular disease in minority populations and serves as a co-investigator in the Cameron County Hispanic Cohort Study. The goals of this endeavor are to understand the prevalence, predictors, and outcomes related to subclinical peripheral arterial disease in Mexican Americans. His research career has led to over 90 publications in peer-reviewed journals. He is an Associate Editor of Catheterization and Cardiovascular Interventions (CCI), Associate Peripheral Arterial Disease Section Editor for SCAI.org, on the ACC Interventional Section writing committee, ACC NCDR PVI Steering committee, XLPAD steering committee and on the editorial board for the Journal of Invasive Cardiology and editorial consultant for the Journal of the American College of Cardiology. The intersection of his research and clinical interests has led to the creation of the largest cardio-renal symposium in the United States: Cardio-Renal Connections. As co-founder of this meeting, Dr. Prasad has worked to bring together clinicians, nurses, students, researchers, and industry to better address the challenges in management of patients with concomitant heart and kidney disease.
Shweta Bansal, MD
After obtaining medical degree from SMS Medical College, Jaipur and Residency in Internal Medicine from New Delhi, India, Dr. Bansal moved to the Unites States in 2001, where she went on to complete Internal Medicine Residency and Nephrology Fellowship from the University of Colorado, Denver. There she also obtained the certificate in Public Health Sciences. Dr. Bansal joined the Division of Nephrology at UT Health San Antonio in 2010 and currently is a clinical Associate Professor of Medicine. Dr. Bansal adores the pathophysiological role kidneys play in health and diseases, particularly the heart and liver failure, and is passionate about teaching this role to the medical students, residents, fellows and colleagues. She has been highly recognized for her outstanding teaching abilities and won several teaching awards. Lately, she has taken over as the Program Director of Nephrology Fellowship Program at UT Health San Antonio.
Dr. Bansal’s research interest focuses on the volume/sodium control in the management of hypertension, kidney and cardiorenal patients. She has also been working on the inflammatory pathways in chronic kidney disease. She has received extra-mural and institutional grants to support her translational and clinical research projects. She is also funded for two new important Precision Medicine initiatives with NIH and consortial funding, and by several clinical industry grants. Lately, Dr. Bansal is getting involved with Health Service Research understanding why clinical research findings are not adopted into clinical practice specifically the hypertension management guidelines regarding diuretics in CKD, and understanding the barriers to implementation. She has over 30 peer-reviewed publication and chapters. Dr. Bansal is an active supporter of the Institutional endeavors and has been chairing one of the Institutional Review Boards since 2015. She is an Associate Editor for Journal Clinical Nephrology. Dr. Bansal clinical interests align with her research interests and involve management of resistant hypertension, cardiorenal syndromes, diabetic nephropathy etc. Dr. Bansal established the peritoneal/home dialysis program at the partnered University Hospital System and fervently promotes this less-utilized modality to the patients and fellows. She also has served as a Medical Director of UHS outpatient renal clinics where she worked on improving patient care by reducing wait times, developing and implementing multiple policies, and streamlining the renal replacement therapy education and dialysis access placement. For patient care, Dr. Bansal strongly believes that the empowerment of patients by health education is the most important step to achieve the best outcomes.
Fruition of Cardio Renal Connections meeting is partly the result of years of Dr. Bansal’s involvement understanding the interaction of kidneys with other organ systems, particularly the heart. This meeting is the perfect venue for providers from different disciplines to come together and discuss the challenges we face on routine basis which are not addressed in specialty-specific conferences. As one of the founders, Dr. Bansal hopes that attendees enjoy this conference as much as she enjoys organizing it.
WHAT IS CARDIO RENAL CONNECTIONS ALL ABOUT?
Cardio Renal Connections is a unique meeting bringing together clinicians and scientists to explore the complex relationships between the heart and kidney. The interplay between the kidneys and the cardiovascular system is complex. The close relationship of renal function and cardiac function has given rise to the concept of cardiorenal syndromes. This interplay extends beyond these syndromes and manifests itself in the form of hypertension, metabolic syndrome, and peripheral vascular disease. With the epidemic of obesity, diabetes, and aging of the United States population, physicians will continue to face a growing number of patients with renal and cardiovascular disease. This interprofessional CE program will serve to help foster education and discussion about the intersection of these two pathophysiologic systems.
CONTRIBUTIONS TO SCIENCE
Robert W. Schrier, Shweta Bansal. Pulmonary hypertension, right ventricular failure, and kidney: different from left ventricular failure? Clin J Am Soc Nephrol 2008; 3(5): 1232-1237
Robert W. Schrier, Shweta Bansal. Diagnosis and management of hyponatremia in acute illness. Curr Opin Crit Care 2008 Dec;14(6):627-34
Shweta Bansal, JoAnn Lindenfeld, Robert W. Schrier. Sodium retention in heart failure and cirrhosis: Potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail. 2009 Jul ;2(4):370-376
Shweta Bansal, David Badesch, Todd Bull and Robert W. Schrier. Role of vasopressin and aldosterone in pulmonary arterial hypertension: A pilot study. Contemp Clin Trials 2009 Sep; 30(5): 392-9. Epub 2009 Apr 16.
Subrata Debnath, Farook Thameem, Tahira Alves, Jacqueline Nolan, Hania Al-Shahrouri, Shweta Bansal, Hanna E. Abboud, and Paolo Fanti. Diabetic Nephropathy Among Mexican Americans. Clinical Nephrology 2012; 77(4):332-44.
Marvin Eng, Shweta Bansal*. Use of Natriuretic-doses of Spironolactone for Treatment of Loop Diuretic Resistant Acute Decompensated Heart Failure. Int J Cardiol. 2014 Jan 1;170(3):e68-9. doi: 10.1016/j.ijcard.2013.11.023. Epub 2013 Nov 12
SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9
Levin D, Bansal S, Prasad A. The Role of Novel Cardiorenal Biomarkers in the Cardiac Catheterization Laboratory for the Detection of Acute Kidney Injury. Rev Cardiovasc Med. 2016;17(3-4):100-114. PMID: 28144017.
Bansal S. New insight into in to an old therapy for the treatment of acute decompensated heart failure and associated renal dysfunction.SM Journal of Cardiology and Cardiovascular Diseases 2016; 2: 1006
Shweta Bansal*, Anand Prasad, Stuart Linas. Right Heart Failure - Unrecognized Causes of Cardiorenal Syndrome. Perspective in Journal of American Society of Nephrology. July 2018; 29: 1795-1798.
SONAR investigators, Hiddo J L Heerspink, Hans-Henrik Parving, Dennis L Andress, George Bakris, Ricardo Correa-Rotter, Fan-Fan Hou, Dalane W Kitzman, Donald Kohan, Hirofumi Makino, John J V McMurray, Joel Z Melnick, Michael G Miller, Pablo E Pergola, Vlado Perkovic, Sheldon Tobe, Tingting Yi, Melissa Wigderson, Dick de Zeeuw. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet, published Online April 15, 2019,
Shweta Bansal, Kristina Munoz, Sonja Brune, Steve Bailey, Anand Prasad, and Chakradhar Velagapudi. Recognizing and Treating Loop-Diuretic Resistant Acute Decompensated Heart Failure with High-dose Spironolactone. Annals of Internal Medicine. Online July 16, 2019